Zynerba Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Zynerba Pharmaceuticals, Inc.‘s stocks are currently a part of 42 hedge funds’ portfolios, which represents 27.24% of the total amount of its stocks outstanding. This makes up a total of 10.97M shares of Zynerba Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -7.98% or -952.15K shares fewer. As for the holding position changes, 26.19% (11) of current hedge fund investors increased the number of shares held, 33.33% (14) of current holders sold a part of the shares held, and 33.33% (14) closed the holdings completely. 7 hedge funds are new holders of Zynerba Pharmaceuticals, Inc. stock in Q2 2022, it is 16.67% of total holders.
Hedge funds holding Zynerba Pharmaceuticals (Q3 2017 – Q2 2022)
| Q3 2017 | 67 |
|---|---|
| Q4 2017 | 64 |
| Q1 2018 | 61 |
| Q2 2018 | 56 |
| Q3 2018 | 66 |
| Q4 2018 | 57 |
| Q1 2019 | 57 |
| Q2 2019 | 72 |
| Q3 2019 | 83 |
| Q4 2019 | 76 |
| Q1 2020 | 71 |
| Q2 2020 | 70 |
| Q3 2020 | 61 |
| Q4 2020 | 53 |
| Q1 2021 | 60 |
| Q2 2021 | 62 |
| Q3 2021 | 52 |
| Q4 2021 | 50 |
| Q1 2022 | 49 |
| Q2 2022 | 42 |
Hedge funds changes in Zynerba Pharmaceuticals positions (Q3 2017 – Q2 2022)
| Q3 2017 | 15 | 24 | 15 | 13 | 0 |
|---|---|---|---|---|---|
| Q4 2017 | 14 | 24 | 15 | 16 | -5 |
| Q1 2018 | 9 | 19 | 15 | 12 | 6 |
| Q2 2018 | 15 | 8 | 21 | 20 | -8 |
| Q3 2018 | 18 | 20 | 14 | 8 | 6 |
| Q4 2018 | 13 | 7 | 26 | 21 | -10 |
| Q1 2019 | 13 | 17 | 16 | 13 | -2 |
| Q2 2019 | 34 | 20 | 7 | 16 | -5 |
| Q3 2019 | 18 | 35 | 12 | 8 | 10 |
| Q4 2019 | 15 | 29 | 17 | 22 | -7 |
| Q1 2020 | 11 | 21 | 24 | 14 | 1 |
| Q2 2020 | 26 | 17 | 20 | 25 | -18 |
| Q3 2020 | 13 | 12 | 27 | 22 | -13 |
| Q4 2020 | 8 | 20 | 12 | 17 | -4 |
| Q1 2021 | 18 | 18 | 10 | 11 | 3 |
| Q2 2021 | 13 | 24 | 15 | 11 | -1 |
| Q3 2021 | 8 | 17 | 16 | 18 | -7 |
| Q4 2021 | 8 | 16 | 16 | 11 | -1 |
| Q1 2022 | 8 | 16 | 14 | 9 | 2 |
| Q2 2022 | 7 | 11 | 14 | 14 | -4 |
Hedge funds changes in Zynerba Pharmaceuticals stock options (Q3 2017 – Q2 2022)
| Q3 2017 | 6,677,000 | 3,116,000 |
|---|---|---|
| Q4 2017 | 1,581,000 | 2,555,000 |
| Q1 2018 | 519,000 | 1,965,000 |
| Q2 2018 | 814,000 | 4,533,000 |
| Q3 2018 | 877,000 | 3,956,000 |
| Q4 2018 | 195,000 | 843,000 |
| Q1 2019 | 877,000 | 2,089,000 |
| Q2 2019 | 11,090,000 | 10,471,000 |
| Q3 2019 | 4,666,000 | 6,316,000 |
| Q4 2019 | 2,590,000 | 5,947,000 |
| Q1 2020 | 681,000 | 2,147,000 |
| Q2 2020 | 7,296,000 | 8,823,000 |
| Q3 2020 | 868,000 | 1,238,000 |
| Q4 2020 | 10,000,000,979,000 | 1,293,000 |
| Q1 2021 | 3,737,000 | 2,740,000 |
| Q2 2021 | 2,915,000 | 2,111,000 |
| Q3 2021 | 1,615,000 | 1,030,000 |
| Q4 2021 | 476,000 | 521,000 |
| Q1 2022 | 106,000 | 120,000 |
| Q2 2022 | 68,000 | 40,000 |